Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1534928

Development of a Tertiary Lymphoid Structure-Based Prognostic Model for Breast Cancer: Integrating Single-Cell Sequencing and Machine Learning to Enhance Patient Outcomes

Provisionally accepted
Xiaonan Zhang Xiaonan Zhang 1Li Li Li Li 1*Xiaoyu Shi Xiaoyu Shi 1*Yunxia Zhao Yunxia Zhao 1*Zhaogen Cai Zhaogen Cai 1Ni Ni Ni Ni 1*Di Yang Di Yang 1*Zixin Meng Zixin Meng 1*Xu Gao Xu Gao 1*Li Huang Li Huang 1*Tao Wang Tao Wang 2*
  • 1 Bengbu Medical Universiy, Bengbu, China
  • 2 Guizhou Provincial People's Hospital, Guiyang, China

The final, formatted version of the article will be published soon.

    Background: Breast cancer, a highly prevalent global cancer, poses significant challenges, especially in advanced stages. Prognostic models are crucial to enhance patient outcomes. Tertiary lymphoid structures (TLS) within the tumor microenvironment have been associated with better prognostic outcomes.We analyzed data from 13 independent breast cancer cohorts, totaling over 9,551 patients. Using single-cell RNA sequencing and machine learning algorithms, we identified critical TLSassociated genes and developed a TLS-based predictive model. This model stratified patients into high and low-risk groups. Genomic alterations, immune infiltration, and cellular interactions within the tumor microenvironment were assessed.The TLS-based model demonstrated superior accuracy compared to traditional models, predicting overall survival. High TLS patients had higher tumor mutation burden and more chromosomal alterations, correlating with poorer prognosis. High-risk patients exhibited a significant depletion of CD4 + T cells, CD8 + T cells, and B cells, as evidenced by single-cell and bulk transcriptomic analyses. In contrast, immune checkpoint inhibitors demonstrated greater efficacy in low-risk patients, whereas chemotherapy proved more effective for high-risk individuals.The TLS-based prognostic model is a robust tool for predicting breast cancer outcomes, highlighting the tumor microenvironment's role in cancer progression. It enhances our understanding of breast cancer biology and supports personalized therapeutic strategies.

    Keywords: breast cancer, tertiary lymphoid structures, machine learning algorithms, Prognostic Prediction Models, immune microenvironment

    Received: 26 Nov 2024; Accepted: 10 Feb 2025.

    Copyright: © 2025 Zhang, Li, Shi, Zhao, Cai, Ni, Yang, Meng, Gao, Huang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Li Li, Bengbu Medical Universiy, Bengbu, China
    Xiaoyu Shi, Bengbu Medical Universiy, Bengbu, China
    Yunxia Zhao, Bengbu Medical Universiy, Bengbu, China
    Ni Ni, Bengbu Medical Universiy, Bengbu, China
    Di Yang, Bengbu Medical Universiy, Bengbu, China
    Zixin Meng, Bengbu Medical Universiy, Bengbu, China
    Xu Gao, Bengbu Medical Universiy, Bengbu, China
    Li Huang, Bengbu Medical Universiy, Bengbu, China
    Tao Wang, Guizhou Provincial People's Hospital, Guiyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more